Abstract: Cervical cancer is associated with the persistent high-risk human papillomavirus（HR-HPV） infection. The test methods of HR-HPV infection have been developed and applied in cervical cancer screening. Four HR-HPV detection methods have been approved in United States and Europe: ①HC2（Hybrid Capture 2）, ②Cervista HR-HPV HR and Cervista HR-HPV 16/18, ③Cobas 4800 HPV, ④Aptima HPV and Aptima 16,18/45. Each method varies in principal and technique, so the indications in the cervical cancer screening strategy are different. The HR-HPV infection detection is applied to find those women at high risk for CINⅡ+, rather than HPV infection. It is possible that the primary HR-HPV screening substitute the cytology-based screening in the future.

Key words: Papillomaviridae, Uterine cervical neoplasms, Infection, Sensitivity and specificity